Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abvc Biopharma Inc
(NQ:
ABVC
)
1.420
-0.170 (-10.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,056,011
Open
1.490
Bid (Size)
1.440 (10)
Ask (Size)
1.460 (7)
Prev. Close
1.590
Today's Range
1.400 - 1.570
52wk Range
0.6739 - 9.600
Shares Outstanding
24,420,526
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
April 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 23, 2024
Via
Benzinga
Performance
YTD
+18.33%
+18.33%
1 Month
+8.40%
+8.40%
3 Month
+2.16%
+2.16%
6 Month
+17.36%
+17.36%
1 Year
-79.12%
-79.12%
More News
Read More
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
April 18, 2024
Via
TheNewswire.com
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
April 18, 2024
Via
NewMediaWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
April 17, 2024
Via
NewMediaWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 10, 2024
Via
Benzinga
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
April 10, 2024
Via
NewMediaWire
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
April 10, 2024
Via
TheNewswire.com
12 Health Care Stocks Moving In Monday's After-Market Session
April 01, 2024
Via
Benzinga
Why ABVC BioPharma Stock Is Up Today
March 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 26, 2024
Via
Benzinga
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
March 26, 2024
Via
NewMediaWire
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
March 26, 2024
Via
TheNewswire.com
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
March 21, 2024
Via
NewMediaWire
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
March 21, 2024
Via
TheNewswire.com
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
March 19, 2024
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
March 19, 2024
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
March 14, 2024
Via
NewMediaWire
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
March 14, 2024
Via
TheNewswire.com
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
February 27, 2024
Via
NewMediaWire
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
February 27, 2024
Via
TheNewswire.com
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
February 15, 2024
Via
NewMediaWire
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
February 12, 2024
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
February 12, 2024
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
February 08, 2024
Via
NewMediaWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.